Marie-José van Tol, PhD, from the University of Groningen.

Preventive Therapy Targeting Positive Affect May Reduce MDD Relapse, With Marie-José van Tol, PhD

New findings suggest preventive cognitive therapy (PCT) may lower relapse risk in remitted recurrent 

by improving pleasure and modifying dysfunctional attitudes.

, Marie-José van Tol, PhD, from the University of Groningen, discussed new data examining the cognitive and affective mechanisms underlying preventive cognitive therapy (PCT), highlighting the role of positive affect and anhedonia in reducing relapse risk.

“In order to change dysfunctional attitudes that are very quite rigid and related to depressive relapse, we need to also focus on increasing the ability to experience pleasure and to up regulate positive emotions,” van Tol said.

The study included 69 unmedicated individuals with remitted MDD at high risk for recurrence from the NEWPRIDE randomized controlled trial. The findings showed a 3-month PCT intervention directly improved consummatory pleasure, the inverse of anhedonia, and increased use of cognitive reappraisal, which together contributed to reductions in dysfunctional attitudes associated with relapse vulnerability. Change in anhedonia (odds ratio [OR], 0.79; 95% CI, 0.68–0.92; 

 =.003] and dysfunctional attitudes (OR, 0.93; 95% CI, 0.86–0.99; 

 =.041) predicted relapse status at 18-month follow-up in PCT-recipients.

The analysis demonstrated that improvements in pleasure mediated the relationship between PCT and reductions in maladaptive beliefs (P =.003). Van Tol described this as a “cross-valence” mechanism, in which strengthening positive affective experiences may buffer against the impact of negative life events.

“It seems that if we focus on improving the ability to have positive feelings, this might lower the impact that negative events have on us, and thereby also lower the impact it has on an individual, and thereby de-learning, in a sense, these negative beliefs about yourself,” she said.

The study focused on unmedicated individuals, but van Tol noted prior evidence suggests PCT may also provide benefit when combined with maintenance antidepressant therapy. She added that the observed mechanisms involving positive affect require further validation in broader populations.

From a practical standpoint, van Tol suggested clinicians consider incorporating strategies that actively promote positive emotional experiences alongside traditional cognitive techniques. These approaches may include encouraging engagement in rewarding activities, fostering savoring of positive experiences, and strengthening emotion regulation skills through reinterpretation of situations. She said these interventions may improve resilience and reduce vulnerability to recurrence.

Although cognitive reappraisal improved following PCT, it did not independently predict relapse in this study. Van Tol indicated that reappraisal likely contributes as part of a broader set of skills rather than as a standalone therapeutic target.

“Focusing on improving a reappraisal probably will not be enough,” van Tol said.

Angeles-Valdez D, van Kleef R, van Valen E, Garza-Villarreal EA, Bockting C, van Tol MJ. The role of cognitive and affective changes in preventing depressive relapse: A network analysis approach to understanding the mechanisms of preventive cognitive therapy. 

Videos

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

One-Time Gene-Editing Therapy Gives Patients “Freedom” From Pain Crisis

An experimental one-time gene-editing cell therapy may have the potential to give patients with 

 “freedom” from frequent medical interventions and pain crises.

According to findings, 27 out of 28 patients treated with renizgamglogene autogedtemcel (reni-cel) did not report any severe vaso-occlusive events after infusion.

nephrology team spoke with the lead author and chair of the Pediatric Hematology – Oncology & Blood and Bone Marrow Transplant Division at Cleveland Clinic Children’s, Rabi Hanna, MD, to discuss how meaningful this data is for this patient population.

“It is not only enough to survive—it is important to thrive for these patients. That’s why, in addition to this, we are excited to report and collect patient-reported outcomes,” Hanna shared. “And we can see, as we shared during ASH, that patient fatigue and physical activity are almost back to normal. So they are thriving, not only surviving.”

What Does Reni-Cel Do, and How Did Hanna Investigate It?

Reni-cel is an investigational clustered regularly interspaced short palindromic repeats (CRISPR)–Cas12a gene-edited autologous hematopoietic stem-cell therapy. The novel, autologous technique is designed to modify a patient’s own blood-forming stem cells to correct the mutation responsible for sickle cell disease, increasing fetal hemoglobin levels to prevent red blood cells from forming into sickle-shaped cells, and improving overall hemoglobin levels to reduce complications from the disease.

The therapy differs from previously approved therapies, Hanna explains, in 2 key ways. First, it uses Cas12a instead of Cas9, offering increased specificity. Secondly, it mimics a natural process, targeting the HBG1 and HBG2 promoters. This is similar to what occurs in individuals with sickle cell disease who remain asymptomatic due to persistently elevated fetal hemoglobin.

Hanna and colleagues examined this underlying mutation in those individuals and aimed to mimic it in a phase 1-2 multicenter, open-label, single-group study where 28 patients were treated with a single infusion of renicel after myeloblative conditioning with busulfan, a high-dose chemotherapy regimen used before allogeneic stem cell transplantation (HCT) to eliminate cancer cells and suppress the immune system.

What Did Investigators See With Reni-Cel-Treated Patients?

According to the results, among 27 patients who had neutrophil and platelet engraftment by the data-cutoff date, neutrophil engraftment, the process where transplanted stem cells begin producing new, healthy blood cells in a patient's bone marrow. occurred after a median of 23 days (range, 14 to 29). Additionally, platelet engraftment, the process where newly transplanted stem cells begin producing platelets, signaling recovery in hematopoietic stem cell transplants, occurred after a median of 25 days (range, 17 to 51).

At month 6, among 18 patients with at least 6 months of available data, the mean (±SD) total hemoglobin level (9.8±1.7 g per deciliter at baseline) had increased to 13.8±1.9 g per deciliter, and the mean percentage of fetal hemoglobin (2.5±2.5% at baseline) had increased to 48.1±3.2%. Both of these measures remained stable.

In terms of pain crisis, 1 patient had 2 severe vaso-occlusive events after infusion. Overall, the adverse events were consistent with those that occur after myeloablative busulfan-based conditioning and autologous hematopoietic stem-cell transplantation.

“Think of the days this is giving them back now. Even in the one patient who did have pain, that patient previously had 6 to 7 pain crises per year and had only 1 event after treatment, in the setting of infection. This is very promising data, and we will continue to follow these patients long term, including pain outcomes and, importantly, organ effects.”

Hanna further notes anecdotal data of improvement in vasculopathy or pulmonary hypertension, remarking that these metrics warrant further study. Additionally, he emphasizes that, given reni-cel is an innovative therapy, investigators will need to continue to monitor for any potential long-term side effects.

Editor’s Note: Hanna reports relevant disclosures with Chiesi USA, Inc., Swedish Orphan Biovitrum AB (Sobi), and Vertex Pharmaceuticals Incorporated.

Hanna R, Frangoul H, Pineiro L, et al. CRISPR-Cas12a Gene Editing of 

 Promoters to Treat Sickle Cell Disease. 

Popat UR, Pasvolsky O, Bassett Jr. R, et al. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. 

https://doi.org/10.1182/bloodadvances.2023010850

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy. 

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Strategic Alliance Partnership

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 kicks off in Las Vegas, Nevada, on Wednesday, April 22, 2026. As the global burden of 

, and other related conditions continues to rise, this year's conference is set to explore the latest evidence-based strategies, clinical innovations, and interdisciplinary approaches that position nutrition as both a therapeutic tool and a foundation for lifelong health.

The meeting is structured to provide relevant, practical, and immediate application of clinical education for endocrinologists, fellows, primary care physicians, physicians assistants, nurse practitioners, nurses, diabetes care and education specialists, clinical pharmacists, registered dietitians, and others in the endocrine care team. This year’s AACE meeting boasts more than 2200 attendees, 110 speakers, and 80 sessions across the 3-day conference.

 editorial team will be on site at the conference, providing written coverage of practice-shifting data as well as interviews with key experts. You can keep up with our comprehensive conference coverage 

. Check out what can be expected from this year’s meeting below:

 who will discuss advances in prediabetes and diabetes prevention as well as multidisciplinary approaches to MASLD and MASH

who will discuss clinical outcomes associated with continuation versus discontinuation of insulin pump therapy in hospitalized adults with diabetes as well as GLP-1 use in type 1 diabetes and obesity

 who will discuss whether clinicians should continue to use BMI when talking about obesity

 who will discuss 2-year results from the CAHtalyst Adult study of crinecerfont in adults with classic congenital adrenal hyperplasia

1. Tirzepatide vs Semaglutide for Glycemic Control and Weight Loss: Updated Network Meta-Analysis of Phase 3 Trials Incorporating 2025 SURMOUNT-5 Data

 Mohamed Ahmed, MD, and Sameer Bhimani, MD

2. Characterization of Proptosis Response Among Responders Treated with Veligrotug in the THRIVE Phase 3 Trial for Active Thyroid Eye Disease (TED)

 Jody Abrams, MD, Steven Leibowitz, MD, Raghu Mudumbai, MD, et al

3. Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Fasting Blood Glucose

Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

4. Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Post Prandial Blood Glucose

5. Correlation of Weight loss and 36-Item Short Form Survey Total score in weight management with Semaglutide injection: Post-hoc Analysis of Phase 3 Study

 Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

6. Relacorilant Treatment Improves Glycemic Control Among Individuals With Endogenous Hypercortisolism and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

 Julie Silverstein, MD, Georgiana Dobri, MD, Atanaska Elenkova, MD, et al

7. Crinecerfont Improves Cardiometabolic Outcomes Associated With Chronic Supraphysiologic Glucocorticoid Exposure: 1-Year Results from CAHtalyst™ Adult

 Oksana Hamidi, DO, MSCS, Irina Bancos, MD, Nicole Reisch, MD, et al.

Articles

AACE Annual Meeting 2026 convenes April 22–24 in Las Vegas with a nutrition-forward agenda amid accelerating burdens of obesity, diabetes, dyslipidemia, and related cardiometabolic disease. The program targets rapid clinical translation for the full endocrine care team and features 2,200+ attendees, 110 speakers, and 80 sessions. Planned expert discussions include diabetes prevention, inpatient insulin pump management, GLP-1 use in type 1 diabetes/obesity, MASLD/MASH multidisciplinary care, BMI’s role in obesity communication, and 2-year crinecerfont data in classic CAH.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

AACE Annual Meeting 2026 Preview: 7 Trials to Know

Silvia Mariel Ferrucci, MD, is an adjunct professor of dermatology at the University of Milan and the head of the the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

New real-world 3-year data from the multinational GLOBOSTAD study suggest that dupilumab therapy (Dupixent) demonstrates sustained efficacy and safety in patients with 

These findings resulted from a poster presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado. These real-world insights in the overall population treated with dupilumab were discussed in a new interview with Silvia Mariel Ferrucci, MD, an adjunct professor of dermatology at the University of Milan and head of the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

 highlights Ferrucci’s responses to inquiries about her team’s findings and their significance in the 2026 treatment landscape:

Can you give an overview of the GLOBOSTAD study and what makes this dataset particularly valuable for understanding long-term outcomes with dupilumab?

GLOBOSTAD is a global study to evaluate the impact of dupilumab (or Dupixent) on disease outcomes in clinical practice. Observational studies like this provide further evidence about the safety and efficacy of approved treatments, like Dupixent, in real-world settings and also allow us to evaluate treatment effect in a large, diverse cohort of patients over time. Long-term evaluation of atopic dermatitis is particularly important as it’s a chronic disease where many factors, including environmental changes, can instigate flare-ups throughout and over the years.

What was the overall design of this study, and how does its real-world, observational nature shape how we should interpret the findings?

The study enrolled patients 12 years of age and older with moderate-to-severe atopic dermatitis who were receiving Dupixent based on country-specific prescribing information. Outcomes were assessed at baseline, 3 months, 6 months and then every 6 months up to 3 years for this interim analysis. The study is ongoing and will evaluate patients for 5 years.

The study adds real-world evidence that further supports the established ability of Dupixent to improve signs and symptoms of atopic dermatitis, but because GLOBOSTAD is not a randomized, placebo-controlled trial, definitive conclusions about safety and efficacy cannot be made based on these results.

At the 3-year mark, what stood out most to you in terms of sustained effectiveness for patients with atopic dermatitis?

In a diverse, real-world population, Dupixent showed sustained effectiveness on measures of disease severity as well as patient-reported symptom severity, itch and health-related quality of life over 3 years compared to baseline. Importantly, the mean values for disease severity, patient-reported symptoms and itch were in the mild/no disease range and patients reported no-to-small effect on health-related quality of life at 3 years of Dupixent treatment.

How did the safety profile of dupilumab evolve over time in this real-world population?

 The safety profile was consistent with the known safety profile of Dupixent. Adverse events occurring in at least 5% of patients included allergic conjunctivitis, COVID-19 and conjunctivitis, with most having resolved or were resolving at the end of the observation period.

 Based on these long-term data, what do you think are the key clinical implications for dermatologists managing patients with moderate-to-severe atopic dermatitis?

Dupixent is already approved for eligible patients with atopic dermatitis in several countries around the world, so long-term, real-world analyses like these provide further evidence about the value Dupixent can bring to reducing disease burden for atopic dermatitis patients in clinical practice. Additionally, GLOBOSTAD will collect data about the impact of Dupixent on outcomes related to coexisting type 2 diseases, like asthma, which could also help inform clinical decision making for patients with comorbid conditions.

The quotes used in this Q&A interview summary were edited for clarity.

Ferrucci has served as a principal investigator in clinical trials for AbbVie, Almirall, Galderma, Leo Pharma, Sanofi, Amgen, and Novartis, Bayer, and received honoraria for lectures for Novartis and Menarini.

Ferrucci S, et al. Dupilumab Shows Sustained Effectiveness and Safety in Patients with Atopic Dermatitis: Real-World Insights from the Overall Population 3 Years into the GLOBOSTAD Multinational Prospective Observational Study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Smith T. Dupilumab Treatment of Atopic Dermatitis Safe for Up to 5 Years in Children, Adults. HCPLive. December 12, 2024. Accessed April 17, 2026. 

https://www.hcplive.com/view/dupilumab-treatment-atopic-dermatitis-safe-up-to-5-years-children-adults

Three-year interim real-world data from the multinational prospective observational GLOBOSTAD cohort support sustained dupilumab effectiveness and a safety profile consistent with established experience in patients ≥12 years with moderate-to-severe atopic dermatitis. Serial assessments from baseline through 36 months showed durable improvements in clinician-assessed severity, patient-reported symptom burden, pruritus, and health-related quality of life, with mean outcomes in the mild/no-disease range at year 3. Common adverse events (≥5%) included conjunctivitis/allergic conjunctivitis and COVID-19, largely resolving by observation end.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average

A population-wide screening program deployed by mobile health units in Detroit, Michigan, found 11-13% had 

 ≥ stage 3,  double the US population’s 6% reported national average.

Additionally, results from the cross-sectional study of the public health outreach program, which used the CKD-EPI 2021 eGFR creatinine formula, found increased incidence among at-risk subgroups, including older individuals, adults who identify as black, and patients with diabetes.

The Gap and Goal Behind CKD Screening in Disadvantaged Communities

“A lot of what we’re striving to do is just get people to want to know their numbers, want to know the information that’s going to lead them to think perhaps differently about prevention, or get awoken to do something more than nothing, which is going to be the only way to take a stage 3 chronic kidney disease patient and keep them off dialysis,” study investigator, Phillip Levy, an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine, shared in an interview with 

This community health program took place in Detroit, Michigan, where 31 to 34% of residents live below the federal poverty line, classifying these neighborhoods as disadvantaged. As such, a majority of individuals reside in environments with social determinants of health that put them at an increased risk for developing CKD. The major social barriers to screening for patients in these communities often remain awareness and access.

HCPLive’s most recent Crisis Point covers the 

cause and effect of neighborhood disadvantage on kidney disease

To address this, the population health program deployed mobile health units across metropolitan Detroit to improve earlier detection of cardiovascular-kidney-metabolic risk factors, decrease area-wide morbidity and mortality, and reduce health disparities.

How Did The Mobile Health Units Operate? What Did We Learn?

5 to 7 Mobile health units were deployed with nonphysician staff, 5 to 6 days per week, to partner locations. After they took a brief medical history, patients ≥ 18 years of age were offered screenings for high blood pressure (BP), diabetes (ie, hemoglobin A[HbA] measurement), and CKD using eGFR.

The cohort included 5128 unique patients with 5973 encounters. Investigators reported that 2293 patients (44.7%) had eGFRs of 60 to 89 mL/min/1.73 m2, whereas 579 (11.3%) had ≥ CKD stage 3(eGFR <60 mL/min/1.73 m2). As reported, patients with older age, Black race, and diabetes, defined as HbA1c ≥6.5%, were associated with higher risks for ≥ CKD stage 3

I think it’s critically important to recognize that when an older individual, an older Black individual, is found to have CKD, it didn’t happen yesterday. It’s been ongoing for a little while,” Levy said. “I’s really important for clinicians to not only impress upon their patients, but educate their patients to be ambassadors for their families and their communities—to say, you’re here, you’re doing the right thing by coming to the doctor’s office today, but what about your aunt, your uncle, your cousin, your mom, your dad?”

A limitation to these findings was an inability to measure urine albumin to creatinine ratio, which investigators suspect, if added, would result in increased rates of CKD stages.

Editor’s Note: Levy report relevant disclosures with Cielo Foundation.

Brook RD, Korzeniewski SJ, Foster B, et al. Screening for Chronic Kidney Disease by Mobile Health Unit Outreach. JAMA Network Open. 2026;9(3):e262312. doi:

https://doi.org/10.1001/jamanetworkopen.2026.2312

Detroit Partnership on Economic Mobility. University of Michigan. Accessed April 16, 2026. 

https://poverty.umich.edu/projects/detroit-partnership-on-economic-mobility/

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.



Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Understanding Patient Preferences in Psoriasis, With Andrew Blauvelt, MD, MBA

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

Highlighting Key IL-23 Innovations in Dermatology, With April W. Armstrong, MD, MPH

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

FDA News

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Orforglipron Availability, Amazon Pharmacy, and Dosing Considerations

Vaiibhav Patel, MD, is a cardiologist at the Ohio State University Wexner Medical Center.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The Current Diagnostic and Treatment Landscape of Cardiac Sarcoidosis, With Vaiibhav Patel, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Hosts are joined by Meena Bansal, MD, to discuss long-standing research gaps and what clinicians need to understand about sex-specific drivers of liver disease today.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: Closing the Gap in Women’s Liver Health

James Murrough, MD, PhD, from the Icahn School of Medicine at Mount Sinai.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

Kv7 Channel Modulator Shows Promise for Anhedonia in MDD, With James Murrough, MD

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease. 

Can Gene Editing Be A 'Functional Cure' For Sickle Cell Disease?

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.


How the AAD Clinical Image Collection Can Help Dermatologists, With Vinod Nambudiri, MD, MBA, MPH

Experts discuss diagnostic challenges, variable presentations, and strategies to improve outcomes in Wilson disease.

From Diagnosis to Management: Addressing Gaps in Wilson Disease Care

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Results from the largest and longest trial of orforglipron to date have displayed the drug’s efficacy in reducing all-cause cardiovascular death and MACE incidence.

Latest News

Preventive Therapy Targeting Positive Affect May Reduce MDD Relapse, With Marie-José van Tol, PhD

One-Time Gene-Editing Therapy Gives Patients “Freedom” From Pain Crisis

AACE Annual Meeting 2026 Preview: 7 Trials to Know

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average